CD8A and neoplasm: Whilst they have been the focus of much vaccine development, as we learn more about the need for T helper support to create effective CD8+ T cell response (96, 97) an approach that utilizes both cDC1 to activate CD8+ T cells and cDC2 to activate CD4+ T cells would give a more robust anti-tumor immune response (98).